For Patients With Cancer
OmniCyte is a preclinical stage biotechnology company focused on developing targeted treatments for unmet needs in cancer therapy.
OmniCyte is developing its own proprietary Immuno-Oncology Platform Technology for
Recombinant targeted immunomodulators (co-stimulators)
Ovarian cancer indication (fifth greatest cancer killer in women)
Small Cell Lung Cancer (the most deadly human malignancies)
and multiple additional indications (Non Small Cell Lung Cancer, Glioma, cancer stem cells, pancreatic, prostate, leukemia)
We have a strong management team and deep bench of advisors and collaborators. Our funding has been provided by Connecticut Innovations, angel investors, NCI SBIR & STTR and LLS Translational Research grants and the founders.
A highly renowned team of scientific researchers specialized in oncology, epidemiology and biochemistry.